BRPI0411864A - combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas - Google Patents

combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas

Info

Publication number
BRPI0411864A
BRPI0411864A BRPI0411864-2A BRPI0411864A BRPI0411864A BR PI0411864 A BRPI0411864 A BR PI0411864A BR PI0411864 A BRPI0411864 A BR PI0411864A BR PI0411864 A BRPI0411864 A BR PI0411864A
Authority
BR
Brazil
Prior art keywords
treatment
combination
kinase inhibitors
proliferative diseases
src kinase
Prior art date
Application number
BRPI0411864-2A
Other languages
English (en)
Inventor
Francis Y F Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0411864A publication Critical patent/BRPI0411864A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçãO DE INIBIDORES DE SRC QUINASE E AGENTES QUIMIOTERáPICOS PARA O TRATAMENTO DE DOENçAS PROLIFERATIVAS". A presente invenção refere-se a métodos e composições os quais são úteis para o tratamento e a prevenção de distúrbios proliferativos.
BRPI0411864-2A 2003-07-09 2004-07-09 combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas BRPI0411864A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48577903P 2003-07-09 2003-07-09
PCT/US2004/021890 WO2005013983A1 (en) 2003-07-09 2004-07-09 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
BRPI0411864A true BRPI0411864A (pt) 2006-08-08

Family

ID=34135068

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411864-2A BRPI0411864A (pt) 2003-07-09 2004-07-09 combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas

Country Status (20)

Country Link
US (2) US20050009891A1 (pt)
EP (1) EP1643996A4 (pt)
JP (1) JP2007528849A (pt)
KR (1) KR20060032627A (pt)
CN (1) CN1849119A (pt)
AU (1) AU2004263095B2 (pt)
BR (1) BRPI0411864A (pt)
CA (1) CA2531675A1 (pt)
GE (1) GEP20094677B (pt)
IL (1) IL173008A0 (pt)
IS (1) IS8221A (pt)
MX (1) MXPA06000191A (pt)
NO (1) NO20060392L (pt)
NZ (1) NZ544587A (pt)
RS (1) RS20060011A (pt)
RU (1) RU2006103858A (pt)
TW (1) TW200505443A (pt)
UA (1) UA83850C2 (pt)
WO (1) WO2005013983A1 (pt)
ZA (1) ZA200600176B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
NZ550114A (en) * 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
US8247419B2 (en) * 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070093499A1 (en) * 2005-10-20 2007-04-26 Bristol-Myers Squibb Company Use of dasatinib for the treatment of bone metastasis
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
JP5622393B2 (ja) * 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
GB0625691D0 (en) * 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
CN101265274B (zh) * 2007-02-16 2013-09-04 中国医学科学院药物研究所 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010025142A1 (en) * 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051910A (en) * 1989-10-16 1991-09-24 Honeywell Inc. Wind forecast error compensation for 4-D guidance in a aircraft flight management system
US5121325A (en) * 1990-04-04 1992-06-09 Smiths Industries Aerospace & Defense Systems, Inc. Required time of arrival (RTA) control system
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6507782B1 (en) * 2001-05-14 2003-01-14 Honeywell International Inc. Aircraft control system for reaching a waypoint at a required time of arrival
EP2258371A1 (en) 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
CA2531675A1 (en) 2005-02-17
US20080153842A1 (en) 2008-06-26
TW200505443A (en) 2005-02-16
ZA200600176B (en) 2010-06-30
UA83850C2 (ru) 2008-08-26
US7622472B2 (en) 2009-11-24
AU2004263095A1 (en) 2005-02-17
US20050009891A1 (en) 2005-01-13
NO20060392L (no) 2006-02-03
GEP20094677B (en) 2009-05-10
IS8221A (is) 2006-01-06
MXPA06000191A (es) 2006-04-11
WO2005013983A1 (en) 2005-02-17
KR20060032627A (ko) 2006-04-17
EP1643996A1 (en) 2006-04-12
IL173008A0 (en) 2006-06-11
RS20060011A (sr) 2007-12-31
NZ544587A (en) 2009-07-31
JP2007528849A (ja) 2007-10-18
CN1849119A (zh) 2006-10-18
AU2004263095B2 (en) 2009-10-29
EP1643996A4 (en) 2009-06-03
RU2006103858A (ru) 2006-06-27

Similar Documents

Publication Publication Date Title
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
BR0208373A (pt) Inibidores da tirosina cinase
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
GEP20094677B (en) Combination of src kinase inhibitors and chemotherapeutic agents for treatment of proliferative diseases
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
ATE424208T1 (de) Proteinkinaseinhibitoren
DE60329326D1 (de) Tace inhibitoren
BRPI0411347A (pt) combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.